Screener
Pulse Biosciences, Inc. PLSE Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Interest income | 600 | 1,129 | 1,193 | 2,384 |
| Other income (expense) | 15 | (22) | (9) | (28) |
| Total other income | 615 | 1,107 | 1,184 | 2,356 |
| Net loss | (24,657) | (19,168) | (43,238) | (35,963) |
| Comprehensive loss | $(24,657) | $(19,168) | $(43,238) | $(35,963) |
| Net loss per share, basic and diluted | $(0.36) | $(0.28) | $(0.63) | $(0.54) |
| Weighted average common shares outstanding, basic and diluted | 69,200,020 | 67,275,608 | 68,600,623 | 67,201,198 |
Document
FAQ
- What is Pulse Biosciences, Inc.'s business segments — net income loss?
- Pulse Biosciences, Inc. (PLSE) reported business segments — net income loss of -$24.66M in Q2 2026.
- What does business segments — net income loss mean?
- This represents the final bottom-line profit or loss for the reporting segment after all revenues, operating expenses, and non-operating items have been accounted for. It is the ultimate measure of the segment's financial performance and contribution to the company's overall value.
Ask your AI about Pulse Biosciences, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude